[
    [
        {
            "time": "2019-03-11",
            "original_text": "U.S. FDA Approves Pfizer’s Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), a Biosimilar to Herceptin®1",
            "features": {
                "keywords": [
                    "FDA",
                    "Pfizer",
                    "TRAZIMERA",
                    "Herceptin",
                    "biosimilar",
                    "approval"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-03-11",
            "original_text": "Stocks Spike on M&A and Retail Sales",
            "features": {
                "keywords": [
                    "stocks",
                    "spike",
                    "M&A",
                    "retail sales"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general market",
                    "retail"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-03-11",
            "original_text": "FDA approves Pfizer's biosimilar to Roche's Herceptin",
            "features": {
                "keywords": [
                    "FDA",
                    "Pfizer",
                    "Roche",
                    "Herceptin",
                    "biosimilar",
                    "approval"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-03-11",
            "original_text": "Conatus' (CNAT) Q4 Earnings Top Estimates, Emricasan in Focus",
            "features": {
                "keywords": [
                    "Conatus",
                    "CNAT",
                    "Q4 earnings",
                    "Emricasan",
                    "top estimates"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-03-11",
            "original_text": "The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's",
            "features": {
                "keywords": [
                    "Zacks",
                    "analyst blog",
                    "J&J",
                    "Lilly",
                    "Pfizer",
                    "AstraZeneca",
                    "Merck"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-03-11",
            "original_text": "Health Care Sector Update for 03/11/2019: AXGT, LCI, HRC, JNJ, PFE, MRK, ABT, AMGN",
            "features": {
                "keywords": [
                    "health care sector",
                    "AXGT",
                    "LCI",
                    "HRC",
                    "JNJ",
                    "PFE",
                    "MRK",
                    "ABT",
                    "AMGN"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 2,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 4,
                "Source_Recency": 3
            }
        }
    ]
]